Free Fatty Acid Receptor Antagonist

AH-7614 is a potent and selective FFA4 (GPR120) antagonist, with pIC₅₀s of 7.1, 8.1, and 8.1 for human, mouse, and rat FFA4, respectively. AH-7614 has selectivity for FFA4 over FFA1 (pIC₅₀<4.6). AH-7614 is able to block effects of both the polyunsaturated ω-6 fatty acid linoleic acid and the synthetic FFA4 agonist.

GW-1100 is a selective GPR40 antagonist with a pIC₅₀ of 6.9.

DC260126 is a potent antagonist of GPR40 (FFAR1). DC260126 dose-dependently inhibits GPR40-mediated Ca²⁺ elevations stimulated by linoleic acid, oleic acid, palmitoleic acid and lauric acid (IC₅₀: 6.28, 5.96, 7.07, 4.58 μM, respectively). DC260126 could protect MIN6 β cells from palmitate-induced ER stress and apoptosis.

MOMBA is a selective FFA2 (Free Fatty Acid Receptor 2) orthosteric agonist that activates receptor signaling pathways by binding to the orthosteric site of FFA2 with high specificity. MOMBA holds potential for research on metabolic and inflammatory diseases.

TUG-2304 is a highly selective free fatty acid receptor 2 (FFA2, GPR43) antagonist that completely suppresses propionate-induced neutrophil migration and respiratory burst. TUG-2304 is applicable to research related to metabolic and inflammatory diseases.

GW-1100 (Standard) is the analytical standard of GW-1100. This product is intended for research and analytical applications. GW-1100 is a selective GPR40 antagonist with a pIC50 of 6.9.

DC260126 (Standard) is the analytical standard of DC260126 (HY-101906). This product is intended for research and analytical applications. DC260126 is a potent antagonist of GPR40 (FFAR1). DC260126 dose-dependently inhibits GPR40-mediated Ca2+ elevations stimulated by linoleic acid, oleic acid, palmitoleic acid and lauric acid (IC₅₀: 6.28, 5.96, 7.07, 4.58 μM, respectively). DC260126 could protect MIN6 β cells from palmitate-induced ER stress and apoptosis.